Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Piromelatine - Neurim Pharmaceuticals

Drug Profile

Piromelatine - Neurim Pharmaceuticals

Alternative Names: Neu-P11

Latest Information Update: 09 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurim Pharmaceuticals
  • Class Sleep disorder therapies
  • Mechanism of Action Melatonin receptor agonists; Serotonin 1A receptor agonists; Serotonin 1D receptor agonists; Serotonin 2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Insomnia; Ocular hypertension; Open-angle glaucoma
  • No development reported Metabolic syndrome

Most Recent Events

  • 31 Jan 2018 Nerium Pharmaceuticals completes a phase II trial in Open angle glaucoma and Ocular hypertension in Spain (EudraCT2016-002281-31)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Insomnia in France (PO, Tablet)
  • 04 Oct 2016 Phase-II clinical trials in Open angle glaucoma in Spain (PO) (EudraCT2016-002281-31)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top